BioStock: Abliva’s NV354 to progress to clinical development

Biopharma company Abliva ended last week on a high note when it announced positive feedback from the MHRA, the UK regulatory authority, regarding its program NV354. The feedback concerns the preclinical package compiled on NV354 and means that the candidate can now progress to clinical development. Abliva aims to initiate a phase I study with NV354 during 2022, meaning that the company can look forward to having two candidates in clinical development.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/09/ablivas-nv354-to-progress-to-clinical-development/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se